Vinci-Biochem Srl
Via Ponte di Bagnolo, 10
50059 Vinci (Firenze) Italy
vb@vincibiochem.it
Tel: +39 0571 568 147 -
 0571 568 135
Fax: +39 0571 568132 - P. IVA 05706610481

 

COVID-19 Research

     

Reagenti per Ricerca su COVID-19:

     
Active Motif AdipoGen Life Sciences Cayman Chemical
Anticorpi Ricombinanti Spike-ACE2 Inhibitors Screening Kit
ACE2 Blocking Antibody
Librerie di antivirali, Kits
     
BPS Bioscience BioVision logoHycult
ACE2 Inhibitor Screening Assay Kit Coronavirus PCR ed molto altro Immunità Innata
     
Mabtech PBL Assay Science Alpha Diagnostics
ELISpot, FluoroSpot, ELISA Interferon ELISA Reagenti per Ricerca sui Vaccini

  

SARS-COV-2 research tools Cayman Antiviral Research Tools Cayman Coronavirus Screening Tools BPS Coronavirus
SARS-COV-2 (COVID-19) research tools Antiviral Research Tools Cayman Coronavirus Screening Tools Cayman Coronavirus BPS
       

Solo per Uso di Ricerca - Non si vende a Privati

 


 

Active Motif 

 

Development & Characterization of Recombinant Human COVID-19 Antibodies

 

Active Motif clones, sequences and expresses the first full human antibody derived from patients infected with COVID-19. For Immediate Release—Shanghai, China and Carlsbad, CA—February 26, 2020.

Active Motif Shanghai (a subsidiary of Active Motif, Inc.), in collaboration with Fudan University and its affiliated Public Health Clinical Center, used its single-cell AbEpic™ screening technology to isolate antibodies from patients recovering from 2019 Coronavirus related pneumonia (COVID-19). The samples were screened to obtain whole human antibody clones that were sequenced, expressed and characterized for binding directly to the Coronavirus. Joe Fernandez, Chairman and Founder of Active Motif stated, “We believe we are the first laboratory in the world to achieve isolation and expression of a full human antibody isolated directly from patients infected with Coronavirus. The discovery and expression of a full human antibody against the COVID-19 virus is of great significance for diagnosis and clinical treatment.” Addressing a fast-moving epidemic requires a nimble approach and support of innovation in research community. For more information, please contact Joseph Fernandez (fernandez@activemotif.com) or Ted DeFrank (defrank@activemotif.com).

   

Recombinant_Antibodies_Active_Motif

Ora disponibili a catalogo i seguenti Anticorpi Umani Ricombinanti:

 

 
 

 

 Adipogen_SARS-COVID

 

Adipogen_SARS-COVID

 

To screen compounds that inhibit the binding of the viral Spike Protein (RBD) to its human receptor ACE2.
AG-48B-0001-KI01 Manual - Data Sheet Same than AG-44B-0007-KI01 but complete with accessory reagents.
 
 

Anticorpi in evidenza:

 
Unique Human Blocking Antibodyanti-ACE2 (human), mAb (AC384)

AG-20A-0037P preservative free

AG-20A-0037

AG-20A-0037B (Biotin)

disponibile anche: anti-ACE2 (human), pAb - AG-25A-0042

 

Flow Cytometry Validated: Human ACE2 Monoclonal Antibody 
unlabeled AG-20A-0032
Biotin-labeled AG-20A-0032B
ATTO488 AG-20A-0032TD
ATTO647N AG-20A-0032TS

 

Proteine in evidenza:

 
ACE2 (human) (rec.) - AG-40B-0192 
HEK293 cells ≥95% Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.
HEK293 cells ≥90% Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.
Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.
 

Other Validated Recombinant Proteins for ACE2 & COVID-19 Research 

Product Name PID Application/Activity
ACE2 (mouse) (rec.) AG-40B-0193 Soluble mouse ACE2 negative control.
SARS-CoV-2 Spike Protein S1 (RBD)(rec.)(His) CHI-B232004 Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) CHI-B232003 Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.
SARS-CoV-2 Nucleocapsid Protein (rec.)(His) CHI-B233501 For drug screening applications.
PLpro (SARS Coronavirus) (rec.) (His) SBB-DE0024 Involved in the processing of the viral polyprotein.
ISG15 (human) (rec.) (Rhodamine 110) SBB-PS0002 PLPro substrate. Inhibits viral budding and acts as IFNγ-inducing cytokine

 

Antiviral Compounds - Potential Small Molecule Therapeutics Against COVID-19:

 

Amastatin . hydrochloride AG-CP3-7003 100938-10-1 Viral entry, ANPEP (Aminopeptidase N) Viral Replication
Camostat mesylate AG-CR1-3716 59721-29-8 Viral entry, TMPRSS2 Viral Replication
Chloroquine . diphosphate AG-CR1-3721 50-63-5 Lysosome function, Zinc ionophore, Immunomodulation Viral Replication
Hydroxychloroquine . sulfate AG-CR1-3720 747-36-4 Lysosome function, Zinc ionophore, Immunomodulation Viral Replication
Darunavir AG-CR1-3712 206361-99-1 Papain-like viral protease (PLVP) Viral Maturation/Replication
Darunavir . ethanolate AG-CR1-3724 635728-49-3 Papain-like viral protease (PLVP) Viral Maturation/Replication
Ebselen AG-CR1-0031 60940-34-3 Main Protease (Mpro)/3C-like Protease Viral Transcription/Replication
Favipiravir AG-CR1-3717 259793-96-9 RNA-dependent RNA polymerases (RdRps) Viral Transcription/Replication
Lopinavir AG-CR1-3715 192725-17-0 Coronavirus endopeptidase C30 (CEP_C30) Viral Maturation/Replication
Mycophenolic acid AG-CN2-0419 24280-93-1 SARS-CoV-2 papain-like protease (PLpro) Viral Replication
Niclosamide AG-CR1-3643 50-65-7 Endosome acidification Viral Replication
Niclosamide . ethanolamine AG-CR1-3644 1420-04-8 Endosome acidification Viral Replication
Nitazoxanide AG-CR1-3723 55981-09-4 Viral hemagglutinin, Viral IE2 Viral Maturation/Transcription/Replication
Oseltamivir . phosphate AG-CR1-3714 204255-11-8 Viral neuraminidase, Release of viral particles Viral Replication
Remdesivir AG-CR1-3713 1809249-37-3 RNA-dependent RNA polymerases (RdRps) Viral Transcription/Replication
Remdesivir Metabolite AG-CR1-3722 1191237-69-0 RNA-dependent RNA polymerases (RdRps) Viral Transcription/Replication
Ribavirin AG-CR1-3719 36791-04-5 RNA-dependent RNA polymerases (RdRps), RNA capping activity, Viral mutation rates, Immunomodulation Viral Transcription/Replication
Ritonavir AG-CR1-3683 155213-67-5 Coronavirus endopeptidase C30 (CEP_C30) Viral Maturation/Replication
Ruxolitinib . phosphate salt AG-CR1-3645 1092939-17-7 JAK1/JAK2, Immunomodulation Viral Replication
Ruxolitinib (free base) AG-CR1-3624 941678-49-5 JAK1/JAK2, Immunomodulation Viral Replication
Shikonin AG-CN2-0487 517-89-5 Main Protease (Mpro)/3C-like Protease Viral Transcription/Replication
Tofacitinib AG-CR1-3625 477600-75-2 JAK1/JAK3, Immunomodulation Viral Replication
Tofacitinib citrate CDX-T0461 540737-29-9 JAK1/JAK3, Immunomodulation Viral Replication
Umifenovir . HCl [Arbidol] AG-CR1-3718 131707-23-8 Viral entry, Fusion into host cells Viral Replication

 

AdipoGen Innate Immunity Flyer
Innate Immunity
Adipogen Immune Checkpoint Reagents 2019
Immune Checkpoint Reagents Adipogen Life Sciences
       
AdipoGen Functional Antibodies
Functional Antibodies - AdipoGen Scarica PDF
Blocking/Neutralizing Antibodies
Adipogen Inflammasome Research
Adipogen Life Sciences
Inflammasome Research
       

 


 

Alpha Diagnostics

 
ELISA Kits and reagents for Infectious Disease and Vaccine research
Infectious animal disease reagents for vaccine research
 
Human Vaccines Research ELISA Animal-Vaccines

 

 


 

Cayman Chemical 

 

SARS-CoV-2 Screening Library – 9003509

Diverse set of compounds. SARS-CoV-2 targets include:

Main protease (3CLpro) | Spike glycoprotein | ACE2 (human) | RdRp (Nsp12) | Endoribonuclease (Nsp15) | Guanine-N7 methyltransferase (Nsp14) | PLpro (Nsp3) | ADP-ribose phosphatase of Nsp3 | BRD2 (human) 

 

Tools to Study SARS-CoV-2-Host Interactions:

cayman-antiviral

Read the Article: Tools to Study SARS-CoV-2-Host Interactions

 

 

Existing Therapeutics for Viral Disease Research:

Cayman antiviral Library

Read the Article: Using Existing Therapeutics Against SARS-CoV-2

     

SARS-CoV-2 related Research Assay Kits

Citrullinated Histone H3 (Clone 11D3) ELISA Kit - 501620

NETosis Assay Kit - 601010

NETosis Imaging Assay Kit - 601750

SARS-CoV-2 qPCR detection 1-plex assay-N - 30661, 100 reactions

 

Using Existing Therapeutics Against SARS-CoV-2

Featured Article from 2020-03-03

 


Note: The products listed in this article are for biomedical research only. They are not for human or veterinary use.

Currently, there are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing FDA-approved drugs that have a known favorable safety profile are being examined for strategies to treat the disease and fast-track a treatment plan. The influenza drug favilavir (favipiravir; sold for research use only under the name T-705) has just been approved as an investigational therapy, and the Ebola virus drug remdesivir is currently undergoing clinical trial in coronavirus patients in China. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.

SARS-CoV-2, formerly known as the 2019 novel coronavirus (2019-nCoV), is a positive-sense, single-stranded RNA virus. This virus shares 79.5% sequence identity with SARS-CoV and uses the same angiotensin converting enzyme 2 (ACE2) receptor as SARS-CoV as a mechanism of cell entry. ACE2 is highly concentrated in airway epithelial cells. An envelope-anchored spike protein mediates coronavirus entry into host cells by binding to the host ACE2 receptor and then fusing viral and host membranes. Coronaviruses, including SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), and infectious bronchitis virus (IBV), fuse at the plasma membrane or use receptor-mediated endocytosis and fuse with endosomes, depending on the cell or tissue type. This virus-receptor interaction facilitates both cross-species and human-to-human transmission of the virus, allowing the viral genome to be delivered to the host cell cytoplasm for replication.

 

Virus-Host Fusion Inhibitors

 

The broad-spectrum antiviral arbidol blocks viral fusion with target membranes, prohibiting viral entry into cells. Because it targets a common critical step for viral replication, it is effective against numerous viruses, including influenza A, B, and C as well as hepatitis B and C. A study has revealed that arbidol can effectively inhibit SARS-CoV-2 infection at a concentration of 10-30 µM in vitro. Besides its antiviral action, arbidol has been reported to produce an immunomodulatory response by inducing interferon production and stimulating the phagocytic function of macrophages.

Blocking virus-host fusion through inhibiting the Abl kinase pathway is also a promising target for the development of antiviral therapies, since this kinase activity is required for entry of coronaviruses. Abl kinases are composed of distinct domains that enable them to act as scaffolds for signaling complexes and to regulate protein function through phosphorylation of downstream targets. Pathogens have been shown to exploit Abl kinase signaling to rearrange F-actin cytoskeleton and trigger phosphorylation of viral effector proteins to facilitate viral-host fusion. A high-throughput screen identified imatinib as an inhibitor of SARS-CoV and MERS-CoV. It is likely that inhibition of Abl interferes with the actin dynamics required for virus-host fusion. Cayman offers several Abl kinase inhibitors that can be used to study the coronavirus membrane fusion step.

Abl Kinase Inhibitors

Imatinib (mesylate)

Saracatinib

GNF-2

GNF-5

See all Abl family & Bcr-Abl inhibitors

In addition to the coronavirus entering the host by binding to the host cell’s ACE2 receptor, participation of ACE in the renin-angiotensin system has been implicated in the acute, accelerated lung fibrosis associated with coronavirus infection. ACE mediates the conversion of angiotensin I to angiotensin II, which interacts with angiotensin II type 1 (AT1) receptors. In some pathological conditions, overactivation of AT1 receptors may lead to damaging events like fibrosis in the liver and lungs, possibly through increasing TGF-β expression. Presumably, a drug that would inhibit ACE, such as lisinopril, or block AT1, like losartan, would have a beneficial effect of mitigating the heavy fibrosis associated with acute cases of SARS infections by shutting down the ACE-angiotensin II-AT1 pathway. ACE inhibitors may further play a role in disallowing viral fusion of the coronavirus to the host cell and entry into the cell, denying its pathway to replication.

See all ACE inhibitors

See all AT1 receptor antagonists

 

Protease Inhibitors

 

After infection, genomic RNA is released into the cytoplasm of the host cell and translated into two long, overlapping polyproteins, pp1a and pp1ab, which are processed by two proteases, the main protease (Mpro or 3C-like protease) and the papain-like protease (PLpro). The hydrolytic activity of these proteases produces multiple functional proteins that are essential to forming the replicase complex for viral replication. Protease inhibitors block the viral life cycle by selectively preventing such proteolytic cleavage. The protein sequences of SARS-CoV Mpro and SARS-CoV-2 Mpro are 96% identical, indicating that protease inhibitors that have shown success against SARS-CoV should have similar efficacy against SARS-CoV-2. Both mycophenolic acid and the hepatitis C virus (HCV) protease inhibitors telaprevir, boceprevir, and grazoprevir have all been shown to bind to the active site of SARS-CoV-2 PLpro and hence, may be useful in preventing viral replication. A molecular docking study also revealed the HIV protease inhibitor indinavir to nearly perfectly overlap the region of the protein pocket of Mpro. Some success has already been shown in treating SARS-CoV-2-infected patients with the HIV protease inhibitors lopinavir and ritonavir in combination with the influenza neuraminidase inhibitor oseltamivir. However, a clinical study aimed to compare arbidol and lopinavir/ritonavir treatment for patients with COVID-19 with lopinavir/ritonavir only, supported lopinavir/ritonavir therapy but not lopinavir/ritonavir plus arbidol therapy. Cayman offers several protease inhibitors that can be used in candidate screens for inhibitors of Mpro and PLpro activity.

HCV Protease Inhibitors HIV Protease Inhibitors​ Influenza Neuraminidase Inhibitors​
Boceprevir
Grazoprevir
Telaprevir
Darunavir
Indinavir (sulfate)
Lopinavir
Nelfinavir (mesylate)
Ritonavir
Oseltamivir Acid
Oseltamivir (Phosphate)​

See all protease inhibitors

 

RNA-Dependent RNA Polymerase Inhibitors

 

Once inside the host cytoplasm, the single-stranded RNA virus serves as an RNA template that is replicated into complementary strands through the action of the RNA-dependent RNA polymerase (RdRp). The initiation step of RNA synthesis involves the addition of a nucleoside triphosphate to the 3’ end. The strand is elongated by repeated nucleotidyl transfer reactions with subsequent nucleoside triphosphates added to generate the complementary RNA. A class of nucleotide analogs have been developed as antiviral drugs to confuse RdRp as they are incorporated into RNA strands and induce non-obligate RNA chain termination. During the 2003 SARS outbreak, the RdRp inhibitor ribavirin in combination with the HIV protease inhibitors lopinavir and ritonavir was shown to reduce the disease course of clinical trial patients. BCX4430 (galidesivir) is in an advanced development stage under the FDA Animal Efficacy Rule to counteract viral threats from coronaviruses, flaviviruses, filoviruses, paramyxoviruses, togaviruses, bunyaviruses, and arenaviruses.

Development of some nucleoside-based therapeutics for SARS-CoV infections has been hampered by their removal via a proofreading 3’-5’ exoribonuclease (ExoN), but Remdesivir, an adenosine nucleoside analog that demonstrates broad-spectrum anti-RdRp activities has been shown to evade ExoN surveillance. Remdesivir was originally developed to treat Ebola virus, but also shows promising efficacy against SARS-CoV and MERS-CoV in pilot studies with an excellent safety profile in clinical trials so far. Remdesivir was used to treat the first US patient infected with SARS-CoV-2, who recovered. It is in phase 3 trials in Wuhan patients infected with SARS-CoV-2, overseen by the China-Japan Friendship Hospital in Beijing (NCT04252664 and NCT04257656). Remdesivir is a prodrug that metabolizes into its active form GS-441524. Cayman offers the following RdRp-targeted drugs that can be used to study viral replication.

 

RdRp Inhibitors

 

BCX4430 (Galidesivir)

GS-441524

Remdesivir

Ribavirin

T-705 (Favipiravir)

See all RdRp Inhibitors

 

Oxysterol-Binding Protein Inhibitors

 

During viral replication, oxysterol-binding protein (OSBP) plays a vital role in producing the membrane-bound viral replication organelles that form at the membrane contact sites between the ER and Golgi. The antifungal drug itraconazole and the natural compound OSW-1, which is being investigated as an anticancer drug, have been identified as functioning through targeting OSBP. While the binding modality of itraconazole is not known, OSW-1 has been shown to affect binding to one of the two established OSBP ligand binding sites. OSW-1 induces a prolonged reduction of cellular OSBP levels and has been shown to inhibit enterovirus replication. Coronaviruses may also be a suitable target for OSBP-targeted compounds.

Oxysterol-binding Protein Inhibitor

Itraconazole

OSW-1

 

Endosomal pH Regulators

 

Viruses entering host cells by endocytosis require an acidic pH in endosomal vesicles for virus-host fusion and to carry out the replication process. The antimalarial agent chloroquine (phosphate) is a weak base that shows broad-spectrum antiviral activities by increasing the endosomal pH required for viral activity. It can impair the replication of viruses by interfering with endosome-mediated viral entry as well as the late stages of replication of enveloped viruses whose glycosylation step requires a low pH for enzyme processing. Chloroquine (phosphate) can also suppress the release of TNFα and interleukin 6, which contribute to inflammatory complications of viral diseases. In multicenter clinical trials conducted in China, chloroquine (phosphate) has demonstrated potent efficacy in treating pneumonia associated with COVID-19.

Endosomal Acidification Inhibitors

Chloroquine (phosphate)

Hydroxychloroquine (sulfate)

 

Conclusion

Various potential targets for development of COVID-19 therapeutics exist along the stages from when a positive-sense, single-stranded RNA virus infects host cells and replicates. With little time available for drug testing and development, the repurposing of approved pharmaceutical drugs provides the most immediate solution for addressing the COVID-19 outbreak. Indeed, knowledge gained from the previous SARS outbreak has placed researchers in an advantageous position of better understanding solutions of how to address long-term treatment of this newly identified coronavirus. With hundreds of antiviral compounds in our catalog and custom synthesis services at the ready, Cayman scientists are poised to support the development of an effective therapeutic strategy against SARS-CoV-2 infection.

 

Further Reading: Uncovering the Role of BRD2 in COVID-19
 

 

Simplify Screening and Hit-Seeking

 

Antiviral Screening Library

  • Consists of 5 plates with >360 antiviral-associated compounds
  • Supplied in a 96-well MatrixTM tube rack format as 10 mM stock solutions in DMSO
  • Includes a variety of compounds with antiviral activity against HIV, hepatitis B virus, hepatitis C virus, influenza, herpes simplex virus, and coronaviruses, among others

We can add or remove specific compounds and provide bar-coded vials

View hundreds of antiviral compounds available from Cayman

 

Don’t see the compound you need? Request a custom synthesis.

       
Cayman Currents Innate Immune Signaling cGAS STING
Cayman Currents
Innate Immune Signaling
cGAS / STING
Immunology and Inflammation
Immunology & Inflammation Cayman
       

 

BPS Bioscience

 

BPS Bioscience Coronavirus BPS Bioscience continues to be a leader in providing products and services to help meet the urgent need for new drugs and vaccines to treat and prevent COVID-19. BPS Bioscience has quickly developed an entire portfolio of recombinant proteins, unique assay kits, pseudovirions, antibodies, and lentiviruses to help researchers understand the pathogenesis of viral disease and to advance research and development of therapeutic drugs and vaccines.  Visit our website frequently to discover our newest product and service offerings.
   

 

BPS Coronavirus Assay Kits


 

ACE2:SARS-CoV-2 Spike S1 Chemiluminescent Assay Kit - 79945

ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit - 79936

SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit - 79931

Spike S1 (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit - 79954

3CL Protease Fluorescent Assay Kit - 79955

ACE2 Inhibitor Screening Assay Kit - 79923

 
 
Lentiviruses
 
 

 


 

 

BioVision

K1461 100 Rxns
 
Soon available: Coronavirus (SARS-CoV-2) PCR Detection Kit K1460 100 Rxns
 
Antibodies
 
A2069 100 µg
A2068 100 µg
A2070 100 μg
A2063 100 μg
A2065 100 μg
A2067 100 μg
A2066 100 μg
A2064 100 μg
A2061 50 µg
A2060 50 µg
 
 
 
 
Recombinant Proteins
 
P1503 10 μg, 50 μg
P1504 10 μg, 50 μg 
P1505 10 μg
P1506 10 μg, 50 μg 
P1507 10 μg, 50 μg 
P1509 10 μg
P1510 10 μg, 50 μg 
P1511 10 μg, 50 μg 
P1508 10 μg, 50 μg 
P1512 10 μg
P1513 10 μg, 50 μg 
P1514 10 μg, 50 μg 
P1520 10 μg
P1515 10 μg, 50 μg 
P1516 10 μg
P1519 10 μg, 50 μg 
P1518 10 μg, 50 μg 
P1517 10 μg 
   
   
 

 

logoHycult

  

ROLE OF COMPLEMENT IN COVID-19 INFECTED PATIENTS?
 
The innate immunity system could be important since it seems to be related in an inflammatory storm in COVID-19 infected patients, whereas complement appears to contribute to damage in lung. There are a few papers that show evidence and 2 small scale clinical trials are in preparation as found in public domain.
 
LITERATURE/CLINICAL TRIALS:
 
RELEVANT HYCULT BIOTECH PRODUCTS
 
•       MBL ELISA Kit - HK323-1HK323-2
•       MASP-2 ELISA Kit - HK326-1HK326-02
•       C3a ELISA Kit - HK354-1HK354-02
•       C3c ELISA Kit - HK368-1HK368-02
•       C3 ELISA Kit - HK366-1HK366-02
•       C5a ELISA Kit - HK349-1HK349-02
•       C5 ELISA Kit - HK390-1HK390-02
•       TCC ELISA Kit - HK328-1HK328-02
•       gC1qR ELISA KitHK362HK362-02
•       C5aR, mAb 20/70 (functional antibody) used is articles 3 and 4 - HM1076-1HM1076-100ug

 

Hycult ELISA KIts

Hycult Elisa Kits

Scarica PDF

Hycult Complemento
Complement and collectins
ELISA kits, Antibodies and proteins for coagulation factors and complement proteins
C1q, C3a, C3c, MASP
 

 

Mabtech

ELISpot and FluoroSpot – methods for SARS-CoV-2 vaccine development

 

Mabtech supplies immune assays and instruments used to study immune responses, especially in vaccine development. The COVID-19 outbreak has increased the demand for several of our products, and many of our customers are currently doing research on or developing vaccines against SARS-CoV-2. We will continue to meet your urgent requests.

 

Focus:

Tuesday, March 31, 2020

 

EliSpot Mabtech
MabTech EliSpot
Find 1 cell in 100,000 with ELISpot
ELISpot is a sensitive assay used to quantify cytokine- or immunoglobulin-secreting cells at the single-cell level.
FluoroSpot Mabtech
Mabtech FluoroSpot
Discover more with FluoroSpot
FluoroSpot combines the sensitivity of ELISpot with the capacity to analyze secretion of several analytes simultaneously.

 

Ferret INF-gamma ELISpot Assay, ELISA Kit, Antibodies

Cat IFN-gamma ELISpot Assay, ELISA Kit, Antibodies

Soon available Chicken IFN-gamma ELISpot Assay and Antibodies

 


 

PBL Assay Science

 

PBL Interferon ELISA Kits
PBL Interferon ELISAs
   
       
       

 


 

 

 

 

 





  • Come Contattarci - Contact Us:

    Semplicemente preferiamo che ci chiami o ci mandi una mail.
    E' anche possibile compilare il modulo contatti

    Vinci-Biochem Srl
    Via Ponte di Bagnolo, 10
    50059 Vinci (Firenze) Italy
    vb@vincibiochem.it
    Tel:+39 0571 568147
    Fax:+39 0571 568132
    P. IVA 05706610481
L o a d i n g